Company Overview
Snapshot
Founded in April 2015 by Jacob Zankel and Prof. Sandu Pitaru, Cytora operates with 11–50 employees. The company has raised $2 million across two funding rounds from Net Capital Ventures and G.O Innovation. In May 2026, Cytora appointed Dr. Thomas Serena, a renowned wound care expert, to its Scientific Advisory Board to advance patient treatment access and data collection for its hOMSC therapy.
Business overview
Cytora is a clinical-stage biotechnology company focused on developing allogeneic stem cell therapies derived from human oral mucosa stem cells (hOMSC). The company aims to establish hOMSC as a standard treatment for severe diseases, including Parkinson’s, Multiple System Atrophy (MSA), Alzheimer’s Dementia, and non-healing diabetic wounds. Operating within the Health Tech & Life Sciences sector, Cytora’s core technology leverages biological cells to address critical unmet medical needs in pharmaceuticals and life sciences.
Strategic signal
In May 2026, Cytora appointed Dr. Thomas Serena, a world-renowned wound care expert, to its Scientific Advisory Board. This strategic addition signals Cytora's commitment to advancing its hOMSC therapy by leveraging top-tier expertise for patient treatment access and data collection, indicating a strong focus on clinical development and market penetration for its stem cell treatments.
Log in to access full profile ›Company Intelligence Q&A
- What is Cytora's primary focus?
- Cytora is a clinical-stage biotechnology company developing allogeneic stem cell therapies from human oral mucosa stem cells (hOMSC) for treating severe diseases such as Parkinson’s, Alzheimer’s Dementia, and non-healing diabetic wounds.
- When was Cytora founded and by whom?
- Cytora was founded in April 2015 by Jacob Zankel and Prof. Sandu Pitaru.
- What significant appointment did Cytora make in May 2026?
- In May 2026, Cytora appointed Dr. Thomas Serena, a world-renowned wound care expert, to its Scientific Advisory Board to lead patient treatment access and data collection for its hOMSC therapy.
- What were the results of Cytora's Phase 1/2a trial for diabetic foot ulcers?
- In April 2025, Cytora reported successful results from its Phase 1/2a trial of stem cell treatment for diabetic foot ulcers.